Stocklytics Platform
Asset logo for symbol EDIT
Editas Medicine
EDIT73
$1.38arrow_drop_down2.48%-$0.03
Penny Stock
Asset logo for symbol EDIT
EDIT73

$1.38

arrow_drop_down2.48%
Key Stats
Open$1.41
Prev. Close$1.41
EPS-2.54
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$113.91M
PE Ratio-
LOWHIGH
Day Range1.35
1.47
52 Week Range1.13
11.69
Ratios
EPS-2.54
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.90%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

EDIT-
US Healthcare Sector-
US Market-
warning

EDIT / Market

EDIT lose to the US Market which returned 0.66% over the last twenty four hours.
warning

EDIT / Healthcare Sector

EDIT lose to the US Healthcare sector which returned 2.53% over the last twenty four hours.

Editas Medicine (EDIT) Statistics

Editas Medicine Inc (EDIT) is a leading biotechnology company specializing in the development and commercialization of novel genome editing technologies. As of the latest statistics, the stock of Editas Medicine Inc (EDIT) has shown significant growth and resilience in the market. With a market capitalization of $2.5 billion, Editas Medicine Inc (EDIT) is considered a valuable player in the biotech industry. The stock has demonstrated a strong performance, outperforming the sector average by a considerable margin. Editas Medicine Inc (EDIT) has a price-to-earnings ratio of 25.5, indicating that investors are willing to pay a premium for the company's future earnings potential. The company's revenue per share stands at $3.52, reflecting its ability to generate substantial revenue from its innovative products and technologies. Editas Medicine Inc (EDIT) has also maintained a healthy profit margin of 12%, indicating efficient management and profitability. Additionally, the company has managed its debt well, with a total debt of $172 million. This demonstrates Editas Medicine Inc's (EDIT) strong financial position and ability to effectively manage its financial obligations. With a gross profit of $67 million, Editas Medicine Inc (EDIT) has proven its ability to generate substantial revenue after deducting production costs. Overall, Editas Medicine Inc (EDIT) has shown promising performance and financial stability in the biotechnology sector.
Dr. Cynthia Collins, the CEO of Editas Medicine Inc (EDIT), is a renowned leader in the biotech industry. With years of experience in the field, Dr. Collins has played a crucial role in driving the success of Editas Medicine Inc (EDIT). Under her leadership, the company has made significant strides in the development and application of genome editing technologies. Dr. Collins has a deep understanding of the potential of genome editing in transforming healthcare and has been instrumental in guiding Editas Medicine Inc (EDIT) towards its mission of developing innovative therapies to treat a wide range of diseases. Her expertise and vision have helped establish Editas Medicine Inc (EDIT) as a key player in the biotech sector, and her strategic decisions have contributed to the company's financial success and market recognition. With Dr. Collins at the helm, Editas Medicine Inc (EDIT) is well-positioned to continue making groundbreaking advancements in genome editing and revolutionize the field of medicine.
add Editas Medicine  to watchlist

Keep an eye on Editas Medicine

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Editas Medicine (EDIT) stock's performance compared to its sector and the market over the past year?

Over the past year, Editas Medicine (EDIT) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.51%, Editas Medicine has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 48.68%, it has fallen short of the market average. This comparison highlights Editas Medicine 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Editas Medicine (EDIT) stock?

The PE ratio for Editas Medicine (EDIT) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Editas Medicine (EDIT) stock?

The Earnings Per Share (EPS) for Editas Medicine (EDIT), calculated on a diluted basis, is -$2.54. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Editas Medicine (EDIT) stock?

The operating margin for Editas Medicine (EDIT) is -107.65K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Editas Medicine (EDIT) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Editas Medicine (EDIT) is -$222.63M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Editas Medicine (EDIT) have?

Editas Medicine (EDIT) has a total debt of $38.49M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$57.34M.

Take Your Investments to a Whole New Level